Back to Search
Start Over
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.
- Source :
- British Journal of Cancer; 9/8/2009, Vol. 101 Issue 6, p951-956, 6p, 1 Color Photograph, 1 Chart, 2 Graphs
- Publication Year :
- 2009
-
Abstract
- <bold>Background: </bold>Class III beta-tubulin (betaIII-tubulin) is expressed in tissues of neuronal lineage and also in several human malignancies, including non-small-cell lung carcinoma, breast and ovarian cancer. Overexpression of betaIII-tubulin in these tumours is associated with an unfavourable outcome and resistance to taxane-based therapies. At present, betaIII-tubulin expression remains largely uncharacterised in prostate cancer.<bold>Methods: </bold>In this report, we evaluated the expression of betaIII-tubulin in 138 different human prostate tumour specimens by immunohistochemistry from patients with hormone-treated or hormone-untreated prostate cancer. betaIII-tubulin expression was also examined in various prostatic cancer cell lines including in androgen-sensitive human prostate cancer cells, LNCaP, grown in androgen-depleted medium in 2D cultures or as tumour xenografts when the host mouse was castrated.<bold>Results: </bold>Whereas moderate-to-strong betaIII-tubulin expression was detected in only 3 out of 74 (4%) hormone-naive tumour specimens obtained from patients who never received hormone therapy, 6 out of 24 tumour specimens (25%) from patients treated for 3 months with neoadjuvant hormone therapy and 24 out of 40 (60%) castration-resistant tumour specimens from chronic hormone-treated patients were found to express significant levels of betaIII-tubulin. These findings were supported by in vitro and in vivo settings.<bold>Conclusion: </bold>Our data indicate that betaIII-tubulin expression is augmented in prostate cancer by androgen ablation and that the expression of this beta-tubulin isoform is associated with the progression of prostate cancer to the castration-resistant state, a stage largely responsible for mortality from prostate cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- PROSTATE cancer
TUBULINS
BREAST cancer
OVARIAN cancer
CANCER hormone therapy
CANCER patients
TUMORS
PATIENTS
PROSTATE tumors treatment
DISEASE progression
RESEARCH
NERVE tissue proteins
IMMUNOHISTOCHEMISTRY
ANIMAL experimentation
RESEARCH methodology
MEDICAL cooperation
EVALUATION research
COMPARATIVE studies
CASTRATION
CELL lines
PROSTATE tumors
MICE
Subjects
Details
- Language :
- English
- ISSN :
- 00070920
- Volume :
- 101
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- British Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 44095398
- Full Text :
- https://doi.org/10.1038/sj.bjc.6605245